TECHNOLOGY

Biozeus developed a patented, small synthetic, peptide platform named "BZ371". This platform offers a novel and unique therapeutic class in different areas of treatment, such as (1) sexual dysfunction, (2) eye diseases and (3) lung diseases. 

BZ371 platform is composed by a new class of therapeutic compounds that acts locally, through topical application, restoring the physiological NO production, without systemic exposure. The peptides of this platform are called Nitric Oxide Synthase-enhancers, being able to induce the endogenous NO production in the target tissue. This unique mechanism of action offers a more constant, safer and prolonged NO supply, solving problems that have plagued NO-based drug development.

BZ371A topical use cause cavernosal corpus blood flow increase, causing vasodilatation and potentializing the erection.Therefore, this technology can be applied to treat erectile dysfuntion as a monotherapy or in combination with PDE5i (due to its synergistic effect). As a first indication, radical prostatectomy patients where chose due to a high unmet medical need and lack of current efficient treatment. For this population, BZ371A can be used as a supportive therapy to maintain penile integrity for those who were submitted to radical prostatectomy. Currently Biozeus is on phase 2 clinical stage. 

( https://clinicaltrials.gov/ct2/show/NCT05558007?term=Biozeus&draw=2&rank=1 )

Other indications are: (i) Erectile Dysfunction subjects that are intolorent or non responders to PDE5i (like Viagra) such as hypertensive and diabetic patients; (ii) Female Sexual Arousal Disorder (FSAD) 

BZ371A peptide eye drop induces IOP reduction and neuroprotective effect around the optical nerve head. Our compound is directed for the treatment of Retinal DIseases (Diabetic Retinopathy, Dry Age Macular Disease and Glaucoma). BZ371A was granted an Orphan Drug Designation (ODD) by the FDA for the treatment of Anterior Ischemic Optic Neuropathy (AION). 

Currently, this project is in preclincal stage.

BZ371B is administered by inhalation, acting as a local vasodilator, and a selective bronchodilator with anti-inflammatory activity. B371B reduces pulmonary arterial pressure being a new therapeutic approach for patients with Pulmonary Arterial Hypertension (PAH). Compared to other PAH drugs: 

(i) BZ371B does not cause systemic hypotension and can be used in combination with current marketed PAH drugs; (ii) BZ371B has a selective pulmonary action, improving ventilation/perfusion ratio. These advantages elects BZ371B as the only therapeutic option for patients with PAH group 3 (PAH secondary to pulmonary diseases, a currently unattended medical need).

Currently, this project is in preclincal stage. 

Other indications are: (i) Acute Respiratory Distress Syndrome (ARDS- like secondary to COVID-19) - BZ371B has the potential to reduce or avoid the hospitalization period in ICU; (ii) Chronic Obstructive Pulmonary Disease (COPD) with or without PAH.